Autolus Therapeutics plc (NASDAQ:AUTL) Receives $9.32 Consensus Target Price from Analysts

Shares of Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) have been assigned a consensus rating of "Buy" from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have covered the stock in the last year is $9.32.

A number of brokerages have recently commented on AUTL. Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, April 10th. Wells Fargo & Company dropped their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 21st. Finally, Truist Financial decreased their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st.

Autolus Therapeutics Price Performance

NASDAQ:AUTL traded up $0.08 during mid-day trading on Tuesday, hitting $1.43. The company's stock had a trading volume of 1,166,007 shares, compared to its average volume of 1,459,501. The business's fifty day moving average is $1.69 and its two-hundred day moving average is $2.54. The stock has a market cap of $380.51 million, a price-to-earnings ratio of -1.18 and a beta of 2.06. Autolus Therapeutics has a 1 year low of $1.11 and a 1 year high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.12. The company had revenue of $0.03 million during the quarter, compared to analysts' expectations of $2.98 million. Analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in shares of Autolus Therapeutics in the fourth quarter valued at about $26,000. Barclays PLC boosted its holdings in Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after buying an additional 10,866 shares during the last quarter. Dumont & Blake Investment Advisors LLC purchased a new stake in Autolus Therapeutics during the 4th quarter worth approximately $35,000. Arkadios Wealth Advisors acquired a new position in shares of Autolus Therapeutics during the fourth quarter valued at approximately $47,000. Finally, Daiwa Securities Group Inc. lifted its position in shares of Autolus Therapeutics by 55.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock valued at $56,000 after acquiring an additional 8,479 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.